InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,658.91
(
0.49%
)
US TECH 100
19,815.60
(
-0.15%
)
Dow Jones
40,887.19
(
1.68%
)
Brent Oil
83.18
(
-1.38%
)
Bitcoin
64,616.65
(
-0.36%
)
Post# of 252610
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 60
Posts 11533
Boards Moderated 0
Alias Born 07/16/2006

jbog

Member Level

Re: None

Friday, 10/30/2015 7:44:37 AM

Friday, October 30, 2015 7:44:37 AM

Post# of 252610
Total company sales growth was also driven by $469 million in global VIEKIRA sales, now approved in 61 countries with additional approvals anticipated throughout the remainder of 2015 and into 2016, as well as strong operational growth from Duodopa, Creon and Lupron

Versus $385M in Q2. (47 Countries)
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up